We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-14.03%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$5.99B
AUM Growth
-$1.53B
Cap. Flow
+$245M
Cap. Flow %
4.09%
Top 10 Hldgs %
62.92%
Holding
100
New
11
Increased
14
Reduced
4
Closed
15

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$280M
2
SION
Sionna Therapeutics
SION
+$171M
3
IRON icon
Disc Medicine
IRON
+$87.7M
4
GERN icon
Geron
GERN
+$74M
5
ETNB
89bio
ETNB
+$50M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$244M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$111M
3
AXSM icon
Axsome Therapeutics
AXSM
+$84.6M
4
VRNA
Verona Pharma
VRNA
+$82.1M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$58.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.82%
2 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLDB icon
51
Solid Biosciences
SLDB
$884M
$16M 0.27%
4,330,446
– –
CBLL
52
CeriBell Inc
CBLL
$693M
$15.8M 0.26%
824,582
– –
NRIX icon
53
Nurix Therapeutics
NRIX
$2.61B
$15.8M 0.26%
1,333,333
– –
INSM icon
54
Insmed
INSM
$28.8B
$15.3M 0.25%
200,000
– –
TSHA icon
55
Taysha Gene Therapies
TSHA
$1.86B
$15.1M 0.25%
10,872,503
– –
PEPG icon
56
PepGen
PEPG
$163M
$15M 0.25%
10,689,545
– –
FDMT icon
57
4D Molecular Therapeutics
FDMT
$552M
$14.7M 0.25%
4,563,211
– –
TARA icon
58
Protara Therapeutics
TARA
$225M
$14.5M 0.24%
3,400,000
– –
LRMR icon
59
Larimar Therapeutics
LRMR
$445M
$13M 0.22%
6,045,351
– –
ELDN icon
60
Eledon Pharmaceuticals
ELDN
$269M
$12.1M 0.2%
3,566,338
– –
ALEC icon
61
Alector
ALEC
$174M
$11.9M 0.2%
9,695,228
– –
SERA icon
62
Sera Prognostics
SERA
$76.8M
$11.2M 0.19%
3,032,808
– –
MBX
63
MBX Biosciences
MBX
$3.23B
$11.2M 0.19%
1,511,334
– –
BCYC
64
Bicycle Therapeutics
BCYC
$279M
$9.28M 0.16%
1,093,477
– –
RCUS icon
65
Arcus Biosciences
RCUS
$3.64B
$8.92M 0.15%
+1,136,364
New +$13.2M
SRZN icon
66
Surrozen
SRZN
$257M
$7.92M 0.13%
679,130
+396,550
+140% +$4.61M
IMTX icon
67
Immatics
IMTX
$1.34B
$7.89M 0.13%
1,750,000
– –
AVTX icon
68
Avalo Therapeutics
AVTX
$1.03B
$7.75M 0.13%
967,000
– –
PCSC
69
DELISTED
Perceptive Capital Solutions
PCSC
$7.72M 0.13%
750,000
– –
DRUG
70
Bright Minds Biosciences
DRUG
$809M
$7.45M 0.12%
206,427
-254,402
-55% -$9.31M
ACRS icon
71
Aclaris Therapeutics
ACRS
$877M
$7.14M 0.12%
4,666,667
– –
ACHC icon
72
Acadia Healthcare
ACHC
$2.97B
$6.58M 0.11%
+217,000
New +$8.27M
BBNX
73
Beta Bionics
BBNX
$624M
$6.12M 0.1%
+500,000
New +$9.32M
XNCR icon
74
Xencor
XNCR
$1.49B
$6.12M 0.1%
575,000
– –
HOWL icon
75
Werewolf Therapeutics
HOWL
$19.5M
$5.97M 0.1%
6,144,881
– –
1 2
3
4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, RA Capital Management held 100 positions worth $5.99B, down 20% from $7.51B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

RA Capital Management deployed $245M of net new capital in Q1 2025, opening 11 new positions and adding to 14 existing holdings. Its largest new stake was Sionna Therapeutics: 10,445,322 shares worth $109M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was 10x Genomics, an estimated $16.8M trimmed.

  • RA Capital Management's largest Q1 2025 buy was Sionna Therapeutics: 10,445,322 shares worth $109M.
  • RA Capital Management added most to Vaxcyte in Q1 2025, an estimated $280M increase.
  • RA Capital Management's biggest Q1 2025 reduction was 10x Genomics, cutting an estimated $16.8M.
  • RA Capital Management fully exited Legend Biotech in Q1 2025, selling an estimated $244M.
  • RA Capital Management's ten largest holdings make up 63% of its $5.99B portfolio in Q1 2025.
  • RA Capital Management opened 11 new positions and closed 15 in Q1 2025.
  • RA Capital Management's portfolio value fell 20% quarter-over-quarter to $5.99B.

Based on RA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.